CompletedNot Applicable

Prephage - Faecal Bacteriophage Transfer for Enhanced Gastrointestinal Tract Maturation in Preterm Infants - Donor Study

Denmark38 participantsStarted 2022-04-01

Plain-language summary

PrePhage - Fecal bacteriophage transfer for enhanced gastrointestinal tract maturation in preterm infants This pilot triol has the primary goal of demonstrating the safety of transferring viruses and proteins from healthy term infants to preterm infants born between gestational age (GA) 26 + 0 and 30+6. The long-term goal is to develop a safe and effective treatment to prevent the severe gut disease called necrotizing enterocolitis (NEC). NEC is a common disease in neonatal intensive care units affecting 5-10% of all admitted patients. 15-30% of the affected children die from the disease, and many of the survivors suffer from the effects of extensive gut surgery. While the disease is caused by many different factors, recent research has shown the gut microbiome to be a central factor in the development of NEC. Furthermore, in the recent years special viruses called bacteriophages have shown potential in the treatment of various diseases. By collecting feces from healthy, term infants and filtering it thoroughly, the investigators can provide a treatment that contains practically only viruses, proteins and nutrients. It is our belief that giving the preterm infants a mix of viruses including bacteriophages will prevent NEC. To do this, the investigators will go through 3 stages: Recruiting and following healthy donor infants to study the microbiota and use feces from them to donate in stage 2 and 3 Examining the safety of the treatment as well as how it works in preterm piglets STAGE 3 will be performed only if stage 2 shows no serious risks for the infants Testing the treatment in preterm infants. 10 preterm infants will receive the treatment and 10 preterm infants will receive placebo. The investigators expect to see no serious side effects to the treatment. The investigators hope, but do not expect to be able to see a beneficial effect of the treatment. If this pilot trial shows promising results, it will be followed be a larger clinical trial.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria for infants * The donor must be of term (\>37+0 weeks GA, \< 41+0 weeks GA), * Be born vaginally with no maternal pre-birth infection, * Be exclusively breastfed un till fulfilled donation at 4 weeks of age, * Have no known predisposition for disease. Exclusion criteria for infants * Antibiotic exposure before collection of faecal material for donation, * Disease between time of birth and collection of feces for donation, * Major congenital anomalies or birth defects, perinatal asphyxia, need for mechanical ventilation or cardiovascular support before time of inclusion. * Positive stool sample for C. difficile toxin, parasites or other pathogens * Positive HIV, HBV, or HCV or CMV * Parents who do not want to know the HIV, HBV or HCV status of the child Inclusion criteria for mothers * Women aged 18-45 and currently healthy * No continuous medical consumption with effects on microbiome * Non-smoking * Ability to give informed consent Exclusion criteria for mothers * Known or high risk of infectious disease such as HIV, HBV, or HCV * Positive CMV IgM during pregnancy * Positive stool sample for C. difficile toxin, parasites or other pathogens * Systemic antibiotic treatment \< 1 months prior to study * New tattoo \< 1 month prior to study * Risky sexual behavior * Gestational diabetes * Family history of inflammatory bowel disease

What they're measuring

Gut microbiome

Timeframe: 1 year

Trial details

NCT IDNCT05272566

SponsorRigshospitalet, Denmark

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-03-20

View on ClinicalTrials.gov More Feeding Patterns trials

Plain-language summary

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.